APRICUS BIO HIGHLIGHTED IN INVESTMENT NEWSLETTER

• San Diego--(BUSINESS WIRE)--Apricus Biosciences ("Apricus Bio") (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT^® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Company is featured as a special stock pick in the October 2010 issue of the KonLin Letter, an independent New York-based investment newsletter (www.konlin.com) published by KonLin Research & Analysis. The investment letter highlights Apricus Bio's proprietary technology and pipeline of 13 clinical and pre-clinical product candidates in various stages of development.

  "We are pleased with this latest recognition by the Wall Street community, which serves to highlight our continued successful efforts to re-brand the Company and pursue the significant product development, out-licensing and partnering opportunities before us," stated Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio.

  About "The KonLin Letter"

  "The KonLin Letter" is a newsletter service that recommends five low-priced selections each month, including a featured stock of the month, and reviews 30-35 different stocks while monitoring a broad range of technical indicators for the best possible Market Timing Advice. For more information go to http://www.konlin.com.

  The opinions expressed in "The KonLin Letter" are those of the analyst and not of Apricus Biosciences, Inc. Apricus Bio does not accept responsibility for the accuracy of any of the information or statements contained in the report. For information provided by Apricus Bio with respect to its business and business prospects, as well as associated risks with an investment in Apricus Bio stock, Please see the Company's reports filed with the Securities and Exchange Commission, copies of which are available at http://www.sec.gov/ and also on the Company's website http://www.apricusbio.com/

  About Apricus Biosciences

  Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT^® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit http://www.apricusbio.com.

  Contacts:

  ---

  Apricus Biosciences, Inc.
  Edward Cox, V.P.
  
  Investor Relations & Corporate Development Apricus Bio, Inc.
  (858) 848-4249
  [email protected]
  
  Apricus Bio Investor Relations
  Paula Schwartz
  
  Apricus Bio, Inc. Rx Communications Group, LLC
  (917) 322-2216
  [email protected]